Search for drugs:
Typing the drug name to query
DABIGATRAN ETEXILATE MESYLATE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- No prolongation of the QTc interval was observed with dabigatran etexilate at doses up to 600 mg.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
4512
38377075
Odds Ratio = 0.0
Drug Property Information
ATC Code(s):
- B01AE07 - dabigatran etexilate mesylate
- B01AE0 -
- B01AE - Direct thrombin inhibitors
- B01A - ANTITHROMBOTIC AGENTS
- B01 - ANTITHROMBOTIC AGENTS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:dabigatran etexilate mesylate
Active Ingredient UNII:SC7NUW5IIT
Drugbank ID:DB06695
PubChem Compound:6445226
PharmGKB:PA165958369
CAS Number:211915-06-9
Dosage Form(s):capsule
Route(s) Of Administrator:oral
Daily Dose:
- 300.0 mg/day B01AE07
Chemical Structure: 
SMILE Code:
CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1
CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.